Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection

References

• EuguiEMAlmquistSJMullerCDAllisonACLymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletionScand J Immunol19913321611731826793
   PubMed Web of Science ®Google Scholar
• GosioBSperimentate su culture pure di bacilli del carbpnchio demostrarano notevole potere antisetticaG Accad Med Torino198361484
   Google Scholar
• FranklinTJCookJMThe inhibition of nucleic acid synthesis by mycophenolic acidBiochem J196911335155245807210
   PubMed Web of Science ®Google Scholar
• MorrisREWangJBlumJRImmunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allograftsTransplant Proc19914232 Suppl 219252063417
   PubMed Web of Science ®Google Scholar
• PlatzKPBechsteinWOEckhoffDESuzukiYSollingerHWRS-61443 reverses acute allograft rejection in dogsSurgery19911104736740discussion 40–41.1925962
   PubMed Web of Science ®Google Scholar
• SollingerHWDeierhoiMHBelzerFODiethelmAGKauffmanRSRS-61443–a phase I clinical trial and pilot rescue studyTransplantation19925324284321346731
   PubMed Web of Science ®Google Scholar
• CarrSFPappEWuJCNatsumedaYCharacterization of human type I and type II IMP dehydrogenasesJ Biol Chem19932683627286272907903306
   PubMed Web of Science ®Google Scholar
• AllisonACEuguiEMMycophenolate mofetil and its mechanisms of actionImmunopharmacology2000472385118
   Web of Science ®Google Scholar
• HuangHDLiuZHZhuXJChenZHLiLSInhibition of mycophenolic acid on NF-kappaB activity in human endothelial cellsActa pharmacol Sin200223764965312100761
   PubMed Web of Science ®Google Scholar
• LaurentAFDumontSPoindronPMullerCDMycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substratesExp Hematol199624159678536794
   PubMed Web of Science ®Google Scholar
• RaabMDaxeckerHKarimiAIn vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cellsClin Chim Acta20013101899811485760
   PubMed Web of Science ®Google Scholar
• AllisonACEuguiEMMechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejectionTransplantation2005802 SupplS18119016251851
   PubMed Web of Science ®Google Scholar
• BullinghamRMonroeSNichollsAHaleMPharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administrationJournal of Clinical Pharmacology19963643153248728345
   PubMed Web of Science ®Google Scholar
• SweeneyMJHoffmanDHEstermanMAMetabolism and biochemistry of mycophenolic acidCancer Res1972329180318094629779
   PubMed Web of Science ®Google Scholar
• StaatzCETettSEClinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipientsClin Pharmacokinet2007461135817201457
   PubMed Web of Science ®Google Scholar
• ShawLMMickRNowakIKoreckaMBraymanKLPharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft functionJ Clin Pharmacol19983832682759549665
   PubMed Web of Science ®Google Scholar
• ShawLMNawrockiAKoreckaMSolariSKangJUsing established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrationsTher Drug Monit200426434735115257062
   PubMed Web of Science ®Google Scholar
• WeberLTShipkovaMLamersdorfTPharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant RecipientsJ Am Soc Nephrol199898151115209697675
   PubMed Web of Science ®Google Scholar
• HaleMDNichollsAJBullinghamREThe pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantationClin Pharmacol Ther19986466726839871432
   PubMed Web of Science ®Google Scholar
• KiberdBALawenJFraserADKeough-RyanTBelitskyPEarly adequate mycophenolic acid exposure is associated with less rejection in kidney transplantationAm J Transplant2004471079108315196064
   PubMed Web of Science ®Google Scholar
• van GelderTLe MeurYShawLMTherapeutic drug monitoring of mycophenolate mofetil in transplantationTher Drug Monit200628214515416628123
   PubMed Web of Science ®Google Scholar
• FillerGMaiILimited sampling strategy for mycophenolic acid area under the curveTher Drug Monit200022216917310774628
   PubMed Web of Science ®Google Scholar
• PawinskiTHaleMKoreckaMFitzsimmonsWEShawLMLimited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimusClin Chem20024891497150412194926
   PubMed Web of Science ®Google Scholar
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study GroupLancet19953458961132113257752752
   PubMed Web of Science ®Google Scholar
• A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study GroupTransplantation1996617102910378623181
   PubMed Web of Science ®Google Scholar
• SollingerHWMycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study GroupTransplantation19956032252327645033
   PubMed Web of Science ®Google Scholar
• HalloranPMathewTTomlanovichSGrothCHooftmanLBarkerCMycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study GroupsTransplantation199763139479000658
   PubMed Web of Science ®Google Scholar
• RemuzziGLestiMGottiEMycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trialLancet2004364943350351215302193
   PubMed Web of Science ®Google Scholar
• RemuzziGCravediPCostantiniMMycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trialJ Am Soc Nephrol20071861973198517460145
   PubMed Web of Science ®Google Scholar
• MathewTHA blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study GroupTransplantation19986511145014549645801
   PubMed Web of Science ®Google Scholar
• OjoAOMeier-KriescheHUHansonJAMycophenolate mofetil reduces late renal allograft loss independent of acute rejectionTransplantation200069112405240910868649
   PubMed Web of Science ®Google Scholar
• Meier-KriescheHUSteffenBJHochbergAMMycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deteriorationTransplantation20037581341134612717227
   PubMed Web of Science ®Google Scholar
• Meier-KriescheHUSteffenBJHochbergAMLong-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejectionAm J Transplant200331687312492713
   PubMed Web of Science ®Google Scholar
• Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study GroupTransplantation19966157227298607174
   PubMed Web of Science ®Google Scholar
• Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study GroupTransplantation19986522352419458021
   PubMed Web of Science ®Google Scholar
• FlechnerSMMinimizing calcineurin inhibitor drugs in renal transplantationTransplant Proc2003353 SupplS118121
   Web of Science ®Google Scholar
• CalneRYWhiteDJThiruSCyclosporin A in patients receiving renal allografts from cadaver donorsLancet197828104513231327
   Web of Science ®Google Scholar
• HariharanSJohnsonCPBresnahanBATarantoSEMcIntoshMJStableinDImproved graft survival after renal transplantation in the United States, 1988 to 1996N Engl J Med2000342960561210699159
   PubMed Web of Science ®Google Scholar
• CurtisJJLukeRGDubovskyEDiethelmAGWhelchelJDJonesPCyclosporin in therapeutic doses increases renal allograft vascular resistanceLancet1986285054774792875236
   PubMed Web of Science ®Google Scholar
• KeoghACalcineurin inhibitors in heart transplantationJ Heart Lung Transplant2004235 SupplS20220615093806
   PubMed Web of Science ®Google Scholar
• SandersCEJrCurtisJJRole of hypertension in chronic renal allograft dysfunctionKidney Int199552S4347
   Web of Science ®Google Scholar
• Smak GregoorPJvan GelderTvan BesouwNMvan der MastBJJNIJWeimarWRandomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reductionTransplantation200070114314810919591
   PubMed Web of Science ®Google Scholar
• AbramowiczDManasDLaoMCyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled studyTransplantation200274121725173412499889
   PubMed Web of Science ®Google Scholar
• SchnuellePvan der HeideJHTegzessAOpen randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimenJ Am Soc Nephrol200213253654311805185
   PubMed Web of Science ®Google Scholar
• DudleyCPohankaERiadHMycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the “creeping creatinine” studyTransplantation200579446647515729174
   PubMed Web of Science ®Google Scholar
• FlechnerSMGoldfarbDModlinCKidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporineTransplantation20027481070107612438948
   PubMed Web of Science ®Google Scholar
• FlechnerSMKurianSMSolezKDe novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two yearsAm J Transplant20044111776178515476476
   PubMed Web of Science ®Google Scholar
• GrinyoJMGil-VernetSCruzadoJMCalcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 yearsTranspl Int2003161182082712879230
   PubMed Web of Science ®Google Scholar
• KreisHCisterneJMLandWSirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipientsTransplantation20006971252126010798738
   PubMed Web of Science ®Google Scholar
• LoAEgidiMFGaberLWComparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantationTransplantation20047781228123515114090
   PubMed Web of Science ®Google Scholar
• StegallMDLarsonTSPrietoMKidney transplantation without calcineurin inhibitors using sirolimusTransplant Proc2003353 SupplS125127
   Web of Science ®Google Scholar
• TheodorakisJSchneebergerHIllnerWDStanglMZankerBLandWNephrotoxicity-free, mycophenolate mofetil-based induction/maintenance immunosuppression in elderly recipients of renal allografts from elderly cadaveric donorsTransplantation proceedings2000321A SupplS9S11
   Web of Science ®Google Scholar
• TranHTAcharyaMKMcKayDBAvoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroidsJ Am Soc Nephrol200011101903190911004222
   PubMed Web of Science ®Google Scholar
• VincentiFRamosEBrattstromCMulticenter trial exploring calcineurin inhibitors avoidance in renal transplantationTransplantation20017191282128711397963
   PubMed Web of Science ®Google Scholar
• LarsonTSDeanPGStegallMDComplete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimusAm J Transplant20066351452216468960
   PubMed Web of Science ®Google Scholar
• FlechnerSMGoldfarbDSolezKKidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugsTransplantation200783788389217460558
   PubMed Web of Science ®Google Scholar
• EkbergHTedesco-SilvaHDemirbasAReduced exposure to calcineurin inhibitors in renal transplantationN Engl J Med2007357252562257518094377
   PubMed Web of Science ®Google Scholar
• SrinivasTRScholdJDGuerraGEaganABucciCMMeier-KriescheHUMycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantationAm J Transplant20077358659417229066
   PubMed Web of Science ®Google Scholar
• VeenstraDLBestJHHornbergerJSullivanSDHricikDEIncidence and long-term cost of steroid-related side effects after renal transplantationAm J Kidney Dis199933582983910213637
   PubMed Web of Science ®Google Scholar
• MontagninoGTarantinoAMaccarioMElliACesanaBPonticelliCLong-term results with cyclosporine monotherapy in renal transplant patients: a multivariate analysis of risk factorsAm J Kidney Dis20003561135114310845828
   PubMed Web of Science ®Google Scholar
• ParrottNRHammadAQWatsonCJLodgeJPAndrewsCDMulti-center, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipientsTransplantation200579334434815699766
   PubMed Web of Science ®Google Scholar
• HricikDEWhalenCCLautmanJWithdrawal of steroids after renal transplantation–clinical predictors of outcomeTransplantation199253141451733083
   PubMed Web of Science ®Google Scholar
• HricikDEO’TooleMASchulakJAHersonJSteroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysisJ Am Soc Nephrol199346130013058130356
   PubMed Web of Science ®Google Scholar
• KasiskeBLChakkeraHALouisTAMaJZA meta-analysis of immunosuppression withdrawal trials in renal transplantationJ Am Soc Nephrol200011101910191711004223
   PubMed Web of Science ®Google Scholar
• SquiffletJPVanrenterghemYvan HooffJPSalmelaKRigottiPSafe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized studyTransplantation proceedings20023451584158612176495
   PubMed Web of Science ®Google Scholar
• VanrenterghemYLebranchuYHeneROppenheimerFEkbergHDouble-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejectionTransplantation20007091352135911087152
   PubMed Web of Science ®Google Scholar
• MatasAJRamcharanTParaskevasSRapid discontinuation of steroids in living donor kidney transplantation: a pilot studyAm J Transplant20011327828312102262
   PubMed Web of Science ®Google Scholar
• MatasAJKandaswamyRHumarALong-term immunosuppression, without maintenance prednisone, after kidney transplantationAnnals of surgery20042403510516discussion 6–7.15319722
   PubMed Web of Science ®Google Scholar
• VincentiFMonacoAGrinyoJKinkhabwalaMRozaAMulticenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetilAm J Transplant20033330631112614286
   PubMed Web of Science ®Google Scholar
• VincentiFSchenaFPParaskevasSHauserIAWalkerRGGrinyoJA randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipientsAm J Transplant20088230731618211506
   PubMed Web of Science ®Google Scholar
• ter MeulenCGvan RiemsdijkIHeneRJSteroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter studyAm J Transplant20044580381015084178
   PubMed Web of Science ®Google Scholar
• GallonLGWinotoJLeventhalJRParkerMAKaufmanDBEffect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant functionClin J Am Soc Nephrol2006151029103817699323
   PubMed Web of Science ®Google Scholar
• PascualJQueredaCZamoraJHernandezDUpdated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetilTransplant Proc20053793746374816386525
   PubMed Web of Science ®Google Scholar
• HardingerKLBrennanDCLowellJSchnitzlerMALong-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetilTranspl Int2004171060961615517170
   PubMed Web of Science ®Google Scholar
• PelletierRPAkinBHenryMLThe impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantationClin Transplant200317320020512780668
   PubMed Web of Science ®Google Scholar
• TierceJCPorterfield-BaxaJPetrillaAAKilburgAFergusonRMImpact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipientsClin Transplant200519677978416313325
   PubMed Web of Science ®Google Scholar
• KnollGAMacDonaldIKhanAVan WalravenCMycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantationJ Am Soc Nephrol20031492381238612937317
   PubMed Web of Science ®Google Scholar
• WangKZhangHLiYSafety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic reviewTransplant Proc20043672068207015518748
   PubMed Web of Science ®Google Scholar
• ChanLMulgaonkarSWalkerRArnsWAmbuhlPSchiavelliRPatient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodiumTransplantation20068191290129716699457
   PubMed Web of Science ®Google Scholar
• BunnapradistSLentineKLBurroughsTEMycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failureTransplantation200682110210716861948
   PubMed Web of Science ®Google Scholar
• BuddeKBauerSHambachPPharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patientsAm J Transplant20077488889817391132
   PubMed Web of Science ®Google Scholar
• SalvadoriMHolzerHde MattosAEnteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patientsAm J Transplant20044223123614974944
   PubMed Web of Science ®Google Scholar
• SalvadoriMHolzerHCivatiGLong-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patientsClinical nephrology200666211211916939067
   PubMed Web of Science ®Google Scholar
• BuddeKGlanderPDiekmannFEnteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipientsTransplant Proc2004362 SupplS524527
   Web of Science ®Google Scholar
• BuddeKKnollGCurtisJSafety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension studyTransplant Proc200537291291515848573
   PubMed Web of Science ®Google Scholar
• LegendreCCohenDZeierMRostaingLBuddeKEfficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studiesTransplant Proc20073951386139117580145
   PubMed Web of Science ®Google Scholar
• PietruckFAbbud-FilhoMVathsalaAMassariPUPo-HuangLNashanBConversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studiesTransplant Proc200739110310817275484
   PubMed Web of Science ®Google Scholar